Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational study of modified BRD-lite in non-transplant-eligible newly diagnosed multiple myeloma
ChiCTR2100043029Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Kunming Medical University
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by First Affiliated Hospital of Kunming Medical University. Primary endpoint: Objective response rate. Started Mar 2021; status: recruiting.
02
Drugs
bortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2100043029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043029.